CNS Pharmaceuticals (NASDAQ: CNSP) gained an opportunity to expand the reach of its novel brain tumor-targeting drug candidate when CEO John Climaco presented the company’s achievements and vision to potential financial backers at the 22nd annual Global Investment Conference sponsored by H.C. Wainwright & Co. (https://ibn.fm/Lqryu).
CNS Pharmaceuticals has been developing unique treatments for primary and metastatic cancers of the brain and central nervous system, including lead drug candidate, Berubicin, which the company is advancing for federal approval in trials to treat the aggressive brain cancer glioblastoma multiforme (“GBM”), according to a company news release (https://ibn.fm/5mppw).
Climaco’s appearance at the three-day investment conference Sept. 14-16 granted the biopharmaceutical company access to the life sciences investment bank’s trading clients and delivered opportunities for interested parties to visit one-on-one with management team members through the conference’s virtual technology platform. A replay of the Sept. 16 presentation will be available on CNS Pharmaceuticals’ website for 90 days following the event.
CNS Pharmaceuticals has achieved a number of key milestones as part of its preparations for filing an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) later this year to launch Phase II clinical trials for Berubicin.
CNS holds a worldwide exclusive license to the Berubicin chemical compound and has obtained all the data from a Phase I clinical trial completed in 2006 that saw some notable successes. Of 25 patients who could be evaluated, 44 percent experienced a statistically significant improvement in clinical benefit and one person obtained lasting results that has left the patient cancer-free as of the last assessment on Feb. 20, 2020, according to the news release.
When the company begins the anticipated Phase 2 trial in the U.S. in Q1 2021, its sublicensee partner, WPD Pharmaceuticals, also intends to launch in Poland a Phase 2 trial for adult GBM patients along with a Phase 1 trial for pediatric patients with GBM. Meanwhile, CNS continues developing a second drug candidate, WP1244, that is a novel DNA binding agent shown in preclinical studies to be 500 times more potent than the chemotherapeutic agent daunorubicin in stopping tumor cell expansion.
H.C. Wainwright & Co.’s annual Global Investment Conference was an ideal place to attract the financial support necessary to help move the projects forward. The Wainwright company is a full-service, client‐focused organization focused on capital markets and equity research in market sectors that hinge on the healthcare and life science industries, the metals and mining industries, the clean tech industry and technology and telecommunications. The conference’s tracks are divided into those four categories as well as a growth track that tackles scaling, leadership and other aspects of small business success (https://ibn.fm/Rp2o5).
For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
immunotherapy against cancer. In many of these cases, the inflammation recurs, and the treatment impacts…
According to a survey conducted by Gallup Center and West Health, most Americans have no…
A study conducted recently in Ohio has found that wastewater can be a vital provider…
UC San Francisco-based scientists have developed a new immunotherapy that was successful in wiping out…
Immunotherapy has transformed cancer treatment, but the approach still faces challenges like lengthy preparation time…
The palpable euphoria surrounding the election of Democratic healthcare professionals to key positions in the…